首页> 外文期刊>Analytical chemistry >Ultrasensitive Plasmonic Biosensors for Real-Time Parallel Detection of Alpha-L-Fucosidase and Cardiac-Troponin-I in Whole Human Blood
【24h】

Ultrasensitive Plasmonic Biosensors for Real-Time Parallel Detection of Alpha-L-Fucosidase and Cardiac-Troponin-I in Whole Human Blood

机译:超敏感等离子体传感器,用于实时平行检测α-L-岩藻糖苷酶和心肌 - 肌钙蛋白 - I中的全血液

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Cancers and many other diseases, such as hepatocellular carcinoma (HCC) and cardiovascular diseases (CVD), have threatened human lives for centuries. Therefore, a novel technique for such disease prediction is in an urgent demand for timely treatment. Biomarkers, alpha-L-fucosidase (AFU) for HCC and cardiac troponin I (cTnI) for CVD, have proven to be essential in the role of disease detection. Herein, we report on an ultrasensitive plasmonic biosensor that converts plasmonic absorption to electrical current in order to detect AFU and cTnI using whole human blood in a real-time and parallel fashion. The detection limit was calculated to be 0.016 U/L for AFU and 0.015 ng/mL for cTnI, respectively. Combined with the versatility of the strategies for different biomarkers, these results demonstrate that the developed biosensor exhibits a promising application for the prediction of cancers and many other diseases.
机译:癌症和许多其他疾病,如肝细胞癌(HCC)和心血管疾病(CVD),威胁着几个世纪以来的人类生活。 因此,这种疾病预测的新技术是对及时治疗的迫切需求。 对于CVD的HCC和心肌肌钙蛋白I(CTNI)的Biomarkers,α-L-浮糖苷酶(AFU)已被证明是疾病检测的作用至关重要。 在此,我们报告超致电等离子传感器,其将等离子体吸收转换为电流,以便以实时和平行的方式使用全部人类血液来检测AFU和CTNI。 检测极限分别计算为AFU的0.016 U / L和CTNI的0.015ng / ml。 结合不同生物标志物的策略的多功能性,这些结果表明,发达的生物传感器对预测癌症和许多其他疾病表现出有希望的应用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号